1-Acetamidocyclopentanecarboxylic acid, also known as **ACPC**, is a **synthetic amino acid** that is **not naturally occurring**. It is a derivative of **cyclopentanecarboxylic acid** with an **acetamide group** attached at the **1-position**.
**Importance in Research:**
ACPC has gained significant attention in research due to its potential in various fields:
* **Drug Development:**
* **Anti-cancer properties:** ACPC has been shown to exhibit promising anti-cancer activity in preclinical studies. It can interfere with **cell proliferation** and **tumor growth**, potentially by inhibiting the **mTOR pathway** involved in cell growth and survival.
* **Neuroprotective effects:** ACPC has also been investigated for its potential **neuroprotective** properties, potentially by reducing **excitotoxicity** and **inflammation** in the brain.
* **Chemical Synthesis:**
* **Chiral building block:** ACPC's **stereochemical structure** makes it a valuable **chiral building block** in organic synthesis. It can be utilized to construct various biologically active molecules with specific chirality.
* **Analytical Chemistry:**
* **Chromatographic standards:** ACPC can be used as a **chromatographic standard** for analyzing other similar compounds, particularly in **pharmaceutical analysis**.
**Current Research:**
Ongoing research focuses on:
* Understanding the detailed mechanism of action of ACPC in different biological systems.
* Evaluating its efficacy and safety in preclinical and clinical trials for various disease indications.
* Exploring the potential of ACPC as a building block for developing novel drugs and other useful compounds.
**Note:**
While ACPC shows promise in research, it is still under investigation. Further research is needed to determine its potential therapeutic applications and safety profile.
ID Source | ID |
---|---|
PubMed CID | 229296 |
CHEMBL ID | 1416412 |
CHEBI ID | 195588 |
SCHEMBL ID | 1573844 |
Synonym |
---|
mls000738007 , |
4854-46-0 |
nsc-22847 |
nsc22847 |
smr000393684 |
1-acetamidocyclopentanecarboxylic acid |
1-(acetylamino)cyclopentanecarboxylic acid |
1-acetamidocyclopentane-1-carboxylic acid |
CHEBI:195588 |
AKOS005362740 |
NCGC00246920-01 |
EN300-73011 |
cyclopentanecarboxylicacid, 1-(acetylamino)- |
cyclopentanecarboxylic acid, 1-acetamido- |
1-acetylaminocyclopentanecarboxylic acid |
niosh/gy2610000 |
cb 1709 |
GY26100000 |
HMS2753O23 |
SCHEMBL1573844 |
CHEMBL1416412 |
A1-00925 |
DTXSID20281738 |
Z234898151 |
FT-0722305 |
CS-0217294 |
1-acetamidocyclopentanecarboxylicacid |
Class | Description |
---|---|
N-acyl-amino acid | A carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
IDH1 | Homo sapiens (human) | Potency | 18.3564 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 5.0119 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |